Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab |
| |
| Affiliation: | 1. College of Civil Engineering, Nanjing Tech University, Nanjing, Jiangsu Province, China;2. State Key Laboratory of Geohazard Prevention and Geoenvironment Protection, Chengdu University of Technology, Chengdu, Sichuan Province, China;3. Distinguished Professor and Program Director, Zhejiang University–University of Illinois Institute, Zhejiang Univ., Haining, Zhejiang 314400, China;4. Research Professor, Dept. of Civil and Environmental Engineering, University of Southern California, Los Angeles, CA 90089, United States;5. Chaired Professor and Formerly Dean, College of Civil Engineering, Nanjing Tech University, China;1. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, via Roma, 67, Pisa 56100, Italy;2. Department of Department of Surgery, Oncology and Gastroenterology -DiSCOG, University of Padua, Padua, Italy;3. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;4. Department of General Surgery and Gastroenterology, IBD Unit, Pisa University Hospital, Pisa, Italy |
| |
| Abstract: | ![]()
Background and aimsThe effects of maintenance infliximab for Crohn's disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab.MethodsCytokine profiles of 35 Crohn's disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6 weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6 weeks after infliximab infusion.ResultsAt baseline, serum levels of IL-23 (p < 0.05), IL-17A (p < 0.01), IFN-γ (p < 0.05), and IL-6 (p < 0.01) were significantly higher in active Crohn's disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period. When serum cytokine levels were compared between groups classified by therapeutic efficacy of infliximab, patients in the non-sustained response group had a significantly higher level of serum IL-17A than those in the sustained response group (p < 0.05). There were also trends toward higher serum IL-23 and IL-12 in the former than in the latter.ConclusionHigher levels of IL-17A, IL-23, and IL-12 at baseline may be predictive markers for poor therapeutic response to maintenance infliximab therapy. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
